Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Indinavir · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Indinavir sulfate | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * At least six months of prior cumulative ZDV therapy. * Qualifying plasma HIV RNA count of \>= 4 log10 copies/ml obtained within 2 weeks of randomization. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions ...
Top 20 of 28 competitors
Indinavir is an investigational small molecule being studied for the treatment of HIV infections. It is being developed by Bristol-Myers Squibb Company and is currently in Phase 3 clinical development. The drug has been evaluated in a completed clinical trial involving patients with HIV infections.
Indinavir is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this small molecule for the treatment of HIV infections. Indinavir is currently in Phase 3 development.
Indinavir is in Phase 3 clinical development for the treatment of HIV infections. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug has completed one Phase 3 trial, and no active trials are currently listed.
Indinavir has been studied in a completed Phase 3 clinical trial with the identifier NCT00002371. The trial, titled "The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine," enrolled 80 participants with HIV infections across the United States, Canada, and Puerto Rico.
Indinavir is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of HIV infections. The drug has completed one Phase 3 trial, but approval status has not been established. It remains under clinical investigation by Bristol-Myers Squibb Company.